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Completeness and accuracy of national
cancer and death registration for outcome
ascertainment in trials—an ovarian cancer
exemplar
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Chloe Karpinskyj2, Robert Woolas6, Martin Widschwendter1, Lesley Fallowfield7, Stuart Campbell8, Steven Skates9,
Alistair McGuire10, Max Parmar2, Ian Jacobs1,11 and Usha Menon2*
Abstract
Background: There is a trend to increasing use of routinely collected health data to ascertain outcome measures in
trials. We report on the completeness and accuracy of national ovarian cancer and death registration in the United
Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
Methods: Of the 202,638 participants, 202,632 were successfully linked and followed through national cancer and
death registries of Northern Ireland, Wales and England. Women with registrations of any of 19 pre-defined ICD-10
codes suggestive of tubo-ovarian cancer or notification of ovarian/tubal/peritoneal cancer from hospital episode
statistics or trial sites were identified. Copies of hospital and primary care notes were retrieved and reviewed by an
independent outcomes review committee. National registration of site and cause of death as ovarian/tubal/
peritoneal cancer (C56/C57/C48) obtained up to 3 months after trial censorship was compared to that assigned by
outcomes review (reference standard).
Results: Outcome review was undertaken in 3110 women on whom notification was received between 2001 and
2014. Ovarian cancer was confirmed in 1324 of whom 1125 had a relevant cancer registration. Sensitivity and
specificity of ovarian/tubal/peritoneal cancer registration were 85.0% (1125/1324; 95% CI 83.7–86.2%) and 94.0%
(1679/1786; 95% CI 93.2–94.8%), respectively. Of 2041 death registrations reviewed, 681 were confirmed to have a
tubo-ovarian cancer of whom 605 had relevant death registration. Sensitivity and specificity were 88.8% (605/681;
95% CI 86.4–91.2%) and 96.7% (1482/1533, 95% CI 95.8–97.6%), respectively. When multiple electronic health record
sources were considered, sensitivity for cancer site increased to 91.1% (1206/1324, 95% CI 89.4–92.5%) and for cause
of death 94.0% (640/681, 95% CI 91.9–95.5%).
Of 1232 with cancer registration, 8.7% (107/1232) were wrongly designated as ovarian/tubal/peritoneal cancers by
(Continued on next page)
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the registry and 4.0% (47/1172) of confirmed tubo-ovarian cancers were mis-registered. In 656 with death
registrations, 7.8% (51/656) were wrongly assigned as due to ovarian/tubal/peritoneal cancers while 6.2% (40/645)
of confirmed tubo-ovarian cancer deaths were mis-registered.
Conclusion: Follow-up of trial participants for tubo-ovarian cancer using national registry data will result in
incomplete ascertainment, particularly of the site due in part to the latency of registration. This can be reduced by
using other routinely collected data such as hospital episode statistics. Central adjudication by experts though
resource intensive adds value by improving the accuracy of diagnoses.
Trial registration: ISRCTN: ISRCTN22488978. Registered on 6 April 2000
Keywords: Outcomes review, Adjudication, Randomised controlled trial, Ovarian cancer, Screening, UKCTOCS,
Registry
Introduction
Currently, most trials use multiple sources for outcome
ascertainment such as case record forms, patient ques-
tionnaires and electronic national health datasets. The
latter includes cancer and death registrations, hospital
administrative records (e.g. hospital episode statistics in
the UK), national audit data and specialised health data-
sets. This is often followed by central adjudication to en-
sure consistency and minimise bias [1]. Central review
requires medical records to be retrieved, checked for
completeness, redacted with regard to any reference to
randomisation group and patient identifiers and the col-
lated information reviewed by a specialist committee.
Given the expensive and time-consuming nature of this
process, there is a clear need to evaluate alternative
strategies.
There has been an explosion in the use of electronic
national datasets for clinical research. As the data quality
of such resources improves and access processes for re-
search become more streamlined, this is likely to be a
less resource-intensive and less costly option for out-
come ascertainment in trials. The use of cancer and
death registration alone is especially relevant to large
randomised controlled trials of cancer screening where
cancer site and disease-specific cause of death (CoD) are
primary outcome measures. Data from the US National
Lung Screening Trial (NLST) suggests that using death
certificate CoD alone (18%; 95% CI 4.2–25.0) would not
have impacted on the published (20%; 95% CI 6.7–26.7)
lung cancer mortality reduction where the process in-
cluded central adjudication [2]. This was also noted in
the Finnish prostate cancer screening trial [3]. How-
ever, other trials have raised concerns about the
completeness and accuracy of such data [4]. In the
Health Insurance Plan of New York breast screening
trial [4], there was no screening benefit based on
death certificates alone whereas analysis performed
using adjudicated data showed a significant effect.
This raises the need for further investigation before
universal adoption.
In the United Kingdom Collaborative Trial of Ovarian
Cancer Screening (UKCTOCS) [5, 6], follow-up relies on
multiple data sources including national electronic
health-related datasets with expert adjudication (by out-
comes review committee) being used for confirmation of
ovarian cancer diagnosis and CoD. This was felt neces-
sary as ovarian cancer often presents late with widely
disseminated disease, heightening the possibility of dis-
ease misclassification. In addition, decreased investiga-
tion in older women, accident and emergency
presentation and mortality within the first month of
presentation could contribute to ovarian cancer being
reported as a malignant neoplasm of unknown origin
(ICD-10 code C80) [7]. The trial data provides an oppor-
tunity to determine the completeness and accuracy of
national ovarian cancer and death registration in Eng-
land, Wales and Northern Ireland using outcomes re-
view as the reference standard.
Methods
Between April 2001 and September 2005, 202,638 post-
menopausal women aged 50–74 from the general popu-
lation were recruited. They were randomised to annual
screening by transvaginal ultrasound (50,639) or a multi-
modal strategy using serum CA125 interpreted by the
Risk of Ovarian Cancer Algorithm (ROCA), followed by
ultrasound as a second-line test (50,640) or control (no
intervention; 101,359) [5, 6]. The full trial protocol is ac-
cessible at https://www.ctu.mrc.ac.uk/studies/all-studies/
u/ukctocs/. Trial registration is ISRCTN22488978. This
analysis is based on data collected prospectively up to
the end of the initial follow-up phase of UKCTOCS
(2001–2014).
Multiple sources were used for the follow-up of trial
participants (Table 1) [6]. Women who provided written
consent for follow-up through national registries were
flagged using their NHS number, date of birth and ad-
dress for cancer and/or death registrations with NHS
Digital (England and Wales) and the Northern Ireland
Cancer Registry and Business Services Organisation
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Health and Social Care Northern Ireland (BSO Northern
Ireland), respectively. Censorship data for the initial ana-
lysis of trial data was 31 December 2014 [6]. The last no-
tification prior to data freeze for trial outcome analysis
was received for both cancer and deaths for England and
Wales on 25 March 2015 (NHS Digital), deaths for
Northern Ireland on 9 April 2015 (BSO, Northern
Ireland) and cancers for Northern Ireland on 15 April
2015 (Northern Ireland Cancer Registry). For women
resident in England, data was also available for 2001–
2012 from Hospital Episodes Statistics (HES) and up to
2014 from the National Cancer Intelligence Network.
Additionally, all women were sent two follow-up postal
questionnaires, 3–5 years after randomisation and in
2014. The UKCTOCS coordinating centre also received
direct notification from the 13 trial centres and trial par-
ticipants or their relatives.
Outcomes review committee
An outcomes review committee (ORC) was set up to
confirm ovarian cancer diagnosis and death. The com-
mittee consisted of two pathologists with specialist inter-
est in gynaecological cancer and two gynaecological
oncologists. The ORC members were independent of
trial conduct and blinded to the randomisation group.
Identification of cases and collation of evidence
Cases were identified for OR based on a cancer/death
registration with any one of 19 preselected International
Classifications of Disease (10th Revision, ICD-10) codes
(WHO 2003) [7] (Supplementary Table 1, see Add-
itional file 1) or a notification of possible ovarian cancer
through the other sources listed above. The preselected
ICD-10 codes were defined at trial initiation as those po-
tentially associated with an underlying ovarian cancer
[6]. Cases with an ICD-10 C80 (n = 936) death registra-
tion and a cancer registration of a non-ovarian malig-
nancy were reviewed by a designated gynaecological
oncologist and excluded from the below process.
Dedicated coordinating centre personnel initiated the
collection of pertinent documents from National Health
Service (NHS) Trusts, general practices, local health au-
thorities, private hospitals and hospices. These included
copies of medical records, histology, cytology reports,
operative notes, diagnostic imaging reports, hospital let-
ters and discharge summaries, multidisciplinary meeting
summaries, chemotherapy/radiotherapy notes and aut-
opsy reports. Procurement of the histology report was
obligatory in cases where pathological examination had
been undertaken. The documents were organised in
chronological order and any direct or indirect mention
of the randomisation group redacted, prior to submis-
sion to ORC. The minimum dataset required for review
comprised three separate documents which could in-
clude, in addition to those listed above, death certificates
and cancer registrations.
Outcomes review
Figure 1 shows a schematic for outcomes review. For all
cases, a cancer review form (Supplementary Figure 1, see
Additional file 2), and where applicable a death review
form (Supplementary Figure 2, see Additional file 3),
was completed. If the reviewer deemed the documenta-
tion adequate, then a cancer diagnosis or CoD was
assigned. An algorithm with detailed rules for site alloca-
tion (Supplementary Figure 3, see Additional file 4) en-
sured robust, reproducible and transparent assignment
in various clinical scenarios. In all cases where there was
a discrepancy regarding ovarian cancer classification be-
tween the reviewer and cancer or death registry, the case
was forwarded to a second ORC member for an inde-
pendent review. If both reviewers were in agreement, the
assigned diagnosis/CoD was accepted. If there was dis-
agreement, a third ORC member independently
reviewed the case and a consensus decision was made
based on the majority view. If a reviewer was unable to
make a definitive diagnosis, the reviewer could request
either further information or review of pathology slides,
or a case discussion at an ORC meeting.
Outcomes review initially used the WHO 2003 [7]
rules for classifying cases into tubo-ovarian or primary
peritoneal. More recently, all the peritoneal cancers were
reviewed and reclassified as tubo-ovarian cancers based
on WHO revised 2014 criteria [8]. This states that peri-
toneal cancers can only be diagnosed when there is no
demonstrable gross or microscopic ovarian or tubal in-
volvement [9].
Analysis
All trial participants were included in this analysis
(Fig. 2). Sensitivities and specificities of cancer/death
registration of ovarian cancer obtained up to 3 months
postcensorship date were calculated, using central
Table 1 Data sources used for cancer and death notification in
UKCTOCS
Data sources for cancer and death notification
National electronic health-related dataset sources
Cancer registry
Death registry
Hospital Episode Statistics (for women resident in England 2001–
2012)
National Cancer Intelligence Network (NCIN) dataset
Postal follow-up questionnaires
Direct communication from participants or their relatives
Information on trial case record forms/trial teams
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adjudication as the reference standard. We also calcu-
lated the sensitivity if all available national electronic
health-related dataset sources (Table 1) were used. The
definitions for sensitivity and specificity were as defined
by the STARD 2015 guidelines (http://www.equator-
network.org/reporting-guidelines/stard).
In addition, in all cases with a cancer registration and/
or death certification, overall agreement of disease site
and CoD between cancer and death registries and OR
was assessed using the Cohen’s kappa (κ) statistic [10],
with confidence intervals calculated using 1000 boot-
strap samples. Zero weighting was applied to all off-
diagonal cell entries.
We also considered the false-negative rate (FNR = 1-
sensitivity) of cancer registration and death certification
over time, with ORC-confirmed diagnosis and CoD as
the gold standard and summarising with a test for pro-
portional trend (Stata package ptrend). This test takes a
standard χ2 test of cancer registration (or death certifica-
tion) versus year, on k = (row-1) × (column-1) degrees of
freedom (df), and partitions the χ2 value into a linear
component (trend test) on 1 df and a ‘departure’ from
linearity component on k-1 df. We excluded the year
2014 from the cancer registration analysis, as during
exploratory analysis there was a large number of missing
registrations.
Funding
The current analysis was funded by a peer-reviewed
NIHR HTA grant (16/46/01) and The Eve Appeal. The
funders were not involved in the analyses nor in the
writing of this report.
Results
Baseline characteristics of the trial population have been
previously described [11]. Of the 202,638 postmeno-
pausal women, 202,632 (99.9%) women were electronic-
ally flagged for cancer and death registrations in the
relevant national registries of England, Wales and
Northern Ireland (Fig. 2).
Performance characteristics of cancer and death
registration for tubo-ovarian cancer
Our algorithm identified 3110 women requiring out-
comes review for tubo-ovarian cancer diagnosis. The
ORC confirmed 1324 as having tubo-ovarian cancer. Of
them, 1125 women had an ovarian, tubal or primary
peritoneal cancer registration. Overall sensitivity and
Fig. 1 Outcomes review process
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specificity of ovarian, tubal or primary peritoneal cancer
registration within 3 months of censorship date were
85.0% (1125/1324; 95% CI 83.7–86.2%) and 94.0%
(1679/1786; 95% CI 93.2–94.8%), respectively (Fig. 2). In
an additional 81 of the 1324 women, we received an
ovarian, tubal or primary peritoneal cancer notification
from other national datasets (death registration 51, HES
27, NCIN 3). If all available national electronic health-
related datasets (Table 1) were considered, sensitivity
would be 91.1% (1206/1324; 95% CI 89.4–92.5%). Fig-
ure 3a and Supplementary Table 2 (see Additional file 2)
show the proportion of missing cancer registrations over
time. Excluding the last year (2014), there was no statis-
tical evidence of a trend in the proportion of missing
cancer registrations (p = 0.261) or any other form of
temporal variability (p = 0.549).
Our algorithm identified 2214 women who died and
required outcomes review for CoD. Only one of these
Fig. 2 Evaluation of national registrations of tubo-ovarian (includes ovarian, fallopian tube and peritoneal cancer) cancer/death compared to the
reference standard (identification through multiple sources, hospital notes retrieval and independent outcomes review)
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women did not have a death registration as she had
died outside the UK. The ORC confirmed 681 as hav-
ing died due to tubo-ovarian cancer. Of them, 605
women had an ovarian, tubal or primary peritoneal
cancer CoD registration (Table 2). Overall sensitivity
and specificity of ovarian, tubal or primary peritoneal
cancer death registration within 3 months of the cen-
sorship date were 88.8% (605/681; 95% CI 86.4–
91.2%) and 96.7% (1482/1533; 95% CI 95.8–97.6%),
respectively (Fig. 2). In the remaining 76 women, 29
women had an ovarian, tubal or primary peritoneal
cancer registration, six had an ovarian cancer HES
record. If all available national electronic health-
related datasets (Table 1) were considered, sensitivity
would be 94.0% (640/681; 95% CI 91.9–95.5%). The
false-negative rates by year are presented in Fig. 3b
(Supplementary Table 2, see Additional file 5). We
found strong evidence of a negative linear trend in
the proportion of missing death certificates (p =
0.00002) but no further departure from that linearity
(p = 0.474).
Agreement of registry- and outcome review-assigned
tubo-ovarian cancer diagnosis
There was a relevant ICD-10 cancer registration in 1474
of the 3110 women who underwent outcomes review for
potential tubo-ovarian cancer (Table 2). One hundred
seven (8.7%; 107/1232) of 1232 cases registered as ovar-
ian, tubal or primary peritoneal cancer were reclassified
on outcome review as malignant neoplasm of unknown
origin (2.7%; 33/1232), no cancer (2.1%; 26/1232) and
other primary cancer (3.9%; 48/1232). Over one third
were endometrial (41.6%; 20/48). About one fourth
(27.1%; 13/48) of the other primary cancers were meta-
static to the ovary.
In addition, 47 (4.0%; 47/1172) of the 1172 women
confirmed as having tubo-ovarian cancer by outcomes
review would have been missed (Table 2). Almost three
fourths of these women were registered as neoplasms of
the ovary of uncertain behaviour (ICD-10 D39.1). The
majority of these were reclassified on outcomes review
as borderline epithelial or non-epithelial ovarian cancer
(ICD-10 C56.0). Majority (80.3%; 10/12) of the missed
Fig. 3 Proportion of missing registrations (includes ovarian (ICD-10 C56), tubal (ICD 10-C57) and peritoneal (ICD-10 C48) registrations) of tubo-
ovarian cancers by year of diagnosis
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invasive epithelial cancers were at an advanced stage
(Table 3). The overall agreement (85.4%; 1259/1474) be-
tween the disease site ascribed by the cancer registries
and those designated by the ORC was moderate
(Cohen’s kappa (κ) 0.55; 95% CI 0.5–0.6).
Agreement of registry- and outcome review-assigned
ovarian cancer deaths
At censorship, 2041 cases had undergone outcomes re-
view and had a relevant ICD-10 death registration. Of
the 656 ovarian cancer death registrations, 92.2% (605/
656) were confirmed on outcomes review. The CoD in
51 (7.8%; 51/656) of 656 women registered as having
died of ovarian, tubal or primary peritoneal cancer were
reclassified on outcome review as non-ovarian. This in-
cludes malignant neoplasm of unknown origin (51.0%;
26/51), other malignancy (37.3%; 19/51) or non-cancer
causes (11.8%; 6/51). Over half of the other cancer
deaths were due to endometrial cancer (52.6%; 10/19)
(Table 2). In addition, 40 (6.2%; 40/645) of 645 women
confirmed by outcomes review as having died of tubo-
ovarian cancer were registered as having died of non-
tubo-ovarian cancer causes (Table 3). The agreement
(86.3%; 1763/2041) between cancer registry and OR was
substantial (kappa 0.78; 95% CI 0.76–0.80).
Discussion
Main findings
Our findings demonstrate that in trials using follow-up
through national cancer registration alone in England,
Wales and Northern Ireland, 15% of tubo-ovarian cancer
cases may be missed. Similarly, the use of national death
registration alone would result in 11% of tubo-ovarian
cancer deaths being missed. The proportions of missing
cancer registrations showed no decline over time unlike
the deficit in disease-specific death registrations. These
rates could be halved if additional national electronic
datasets such as hospital episode statistics are used.
When extrapolating these results, two facts must be
taken into consideration. We included cancer and death
registrations of primary peritoneal cancer in ovarian can-
cer incidence and mortality statistics. This is not the
norm adopted by the UK Office of National Statistics or
US SEER Registries. We obtained final follow-up data
from the registries 3 months after the censorship date in
order to fulfil reporting guidelines for the trial. Longer
intervals from censorship to obtaining registry data are
likely to reduce the rate in the last year.
Adjudication by an independent review process can
improve the accuracy of cancer and death registrations.
In those where a cancer registration was available, 9% of
registry reported tubo-ovarian cancers would have
Table 2 National cancer and death registrations versus outcomes review confirmation of tubo-ovarian cancer (a) diagnosis and (b)
cause of death










a. Diagnosis (primary cancer site)
Ovarian/tubal or primary peritoneal cancer
(ICD-10 C56 /C57/C48)
1125 33 26 48b 1232
Malignant neoplasm of unknown origin (C80) 9 91 7 48 155
Benign and ovarian neoplasms of uncertain
behaviour (ICD-10 D39.1)
36 0 25 4 65
Other primary cancers 2 2 0 18 22
Total with registry and outcomes review 1172 126 58 118 1474
b. Cause of death
Ovarian/tubal or primary peritoneal cancer
(ICD-10 C56 /C57/C48)
605 26 6 19c 656
Malignant neoplasm of unknown origin (C80) 27 272 10 117 426
Benign and ovarian neoplasms of uncertain
behaviour (ICD-10 D39.1)
2 0 4 0 6
Other primary cancer 11 58 2 882 953
Total 645 356 22 1018 2041
aWHO 2014, includes cancers previously classified as primary peritoneal cancer
bendometrium 20; leiomyosarcoma broad ligament 4; cervix 1; appendix 3; cecum 1; small bowel 2; bile duct 1; breast 2; colon 5; GI stromal 1; lung 1; NHL 3;
pancreas 1; skin 1; small lymphocytic lymphoma 1; vulva 1
cendometrium (10), colon (3), and one each due to breast cancer, peritoneal mesothelioma, kidney cancer, T cell non-Hodgkin’s lymphoma, lung cancer and oral
squamous cell carcinoma
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inaccurate cancer site assignment. Additionally, 4% of
the final outcomes confirmed cancers would have been
missed as they were registered as non-ovarian cancers.
Reliance on death registration alone would have resulted
in a similar proportion (7.8%) of deaths being wrongly
assigned to tubo-ovarian cancers and 6.2% of ovarian
cancer deaths being missed.
Strengths and limitations
A key strength of our analysis is that we compared can-
cer diagnoses and causes of death reported by the na-
tional registries of England, Wales and Northern Ireland
with those assigned through independent central adjudi-
cation in a population cohort of over 3000 women. Of
the 202,638 women, 202,632 (99.9%) women were
Table 3 Characteristics of additional tubo-ovarian cancer (a) cases and (b) deaths identified through adjudication that did not have
a national cancer registration
Registry assigned Designation Following Outcomes Review
Number Histology Morphology Stage
(a) Diagnosis (n = 47)
Neoplasm of uncertain behavior of ovary (ICD-10 D39.1) 27 Borderline 1 Brenner 1 Stage I
3 Endometrioid 3 Stage 1a
9 Mucinous 7 Stage 1a, 2 Stage 1c
14 Serous 9 Stage 1a, 3 Stage 1c, 1
Stage 111a, 1 Stage 111b
8 Non-
epithelial
7 Granulosa cell 4 Stage Ia, 2 Stage 1c, 1
Stage IIb
1 Carcinoid 1 Stage Ia
1 Invasive
epithelial
1 Carcinosarcoma 1 Stage IIIc
Malignant neoplasm without specification of site (ICD-10 C80) 9 Invasive
epithelial
2 Carcinoma 2 Stage IV
1 Carcinosarcoma 1 Stage IV
1 Endometroid 1 Stage IV
5 Serous 1 Stage Ia, 1 Stage IIIa, 1
Stage IIIb, 1 Stage IIIc, 1
Stage IV
Other primarya 1 Invasive
epithelial
1 Serous 1 Stage IIIc
1 1 Clear cell 1 Stage IIb
(b) Cause of death (n = 40)









10 Carcinoma 5 Stage IIIc; 5 Stage IV
14 Serous 1 Stage Ic; 1 Stage IIIb; 8
Stage IIIc; 3 Stage IV;
Multiple registrations which include malignant neoplasm without
specification of site (ICD-10 C80) as well as nonovarian cancer
10 Invasive
epithelial
2 Carcinoma 1 Stage IIIc; 1 Stage IV
5 Serous 4 Stage IIIc; 1 Stage IIIa




1 Serous 1 Stage III




1 Carcinoma 1 Stage IIIc
Carcinoma in situ of other and unspecified genital organs (ICD-10
D07.9)
1 1 Serous 1 Stage IIIb
Neoplasm of uncertain behavior of ovary (ICD-10 D39.1) 1 1 Serous 1 Stage II b
aMalignant neoplasm of pelvis (ICD10 - C76.3); Malignant neoplasm of retroperitoneum (ICD10 - C48.0)
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electronically flagged using their NHS number to the
relevant national cancer and death registries. The mul-
tiple additional data sources (Table 1) we used to iden-
tify potential ovarian cancer cases further ensured that
we had a complete population dataset of cases.
We did not restrict the study to women with the tubo-
ovarian cancer-specific ICD-10 codes (C56, C57.0, C48.1
and C48.2) but used 19 possible ICD-10 codes, in par-
ticular malignant neoplasm primary site unknown (ICD-
10 C80) that might have potentially included tubo-
ovarian cases.
The peritoneal cancers reported by cancer registries
were included as tubo-ovarian in this analysis. While this
is the norm among clinicians and researchers, these can-
cers are not included in national tubo-ovarian statistics.
We did this to ensure that registry completeness rates
were not underestimated due to the 2014 WHO revision
of the primary site definition [8]. As the latter is adopted
by pathology departments the world over, it is likely that
cancers previously denoted as primary peritoneal will be
registered as tubo-ovarian.
A limitation is that the cases were diagnosed over a
prolonged period between 2001 and 2014. To address
this, we explored time trends. While there were no time
trends in missing cancer registration data, the complete-
ness of death registration data improved over the years.
Interpretation
The use of UK cancer registry data alone would have
allowed us to detect 85% of the tubo-ovarian cancer
cases. This is an improvement from the 78% sensitivity
that we reported in our previous trial where women
were diagnosed with these cancers between 1986 and
1993 [12]. It is likely that the rates have improved fur-
ther in the more recent years. The use of multiple na-
tional electronic data sets especially hospital
administration records can augment these rates. A re-
cent report on tubo-ovarian cancers diagnosed between
2004 and 2012 in Switzerland also found that the hos-
pital registry data provided complementary information
to that from the cancer registries [13]. Sourcing data dir-
ectly from live healthcare systems allows trials to over-
come the latency in the national cancer registration
systems. A median latency of 18 (range 4–60) months to
completion of incidence ascertainment was reported in a
recent survey of the European Network of Cancer Regis-
tries [14].
The overall agreement regarding ovarian cancer site
between OR and cancer registries was moderate. A key
area of discrepancy was related to tumours defined by
the ICD-10 code D39.1, neoplasms of the ovary of un-
known or uncertain behaviour. On outcome review, the
majority were reclassified as malignant neoplasm of the
ovary (ICD-10 codes C56), either borderline epithelial
ovarian or granulosa cell tumours. Most of these dis-
crepancies likely reflect historical coding practices and
classification systems used by regional registries prior to
centralization of services in 2013. Furthermore, coding
for ovarian cancers since 2011 uses the ICD-O-3 system
[15], where the topographical code (site of cancer) is
clearly separated from the morphological code which in-
cludes the behaviour (malignant/benign). In the current
system, as borderline ovarian tumours are classified as
C56 (topographical code) with a morphology code of 1,
there is less likelihood of the cases not being registered
as ovarian cancer. However, our data for 2012 to 2014
are not sufficiently large to confirm this.
The 9% of tubo-ovarian cancers reported by the regis-
tries that were classed as ‘not ovarian’ cancers on review
were equally distributed between three main groups: (1)
miscoding of a benign mass as a cancer, (2) other pri-
mary cancer, and (3) malignant neoplasm, primary site
unknown (C80). The other primary group included just
under a third of cancers that metastasized to the ovary,
which might have led to the confusion. The ovaries are a
frequent site for metastases, with 5–30% of ‘ovarian
masses’ being secondary metastasis reported from non-
ovarian cancers [16].
The cause of death on death certificates is not always
accurate [17] due to a variety of reasons (inexperience of
certifying physician, lack of sufficient time/information,
coding errors). However, in our trial, there was substan-
tial agreement regarding the primary site between the
death registry-reported ovarian cancer deaths and those
assigned by the review committee. This has also been re-
ported in screening trials of other cancers (e.g. prostate)
which used adjudication panels [18, 19]. Nonetheless,
6.2% additional tubo-ovarian cancer deaths were identi-
fied through the adjudication process. A high proportion
were registered as malignancies with an unknown pri-
mary site (C80) and all were at an advanced stage. In ad-
vanced cancer, where multiple sites are involved, it may
be difficult to assign the primary site [20]. The lack of
consistency in the approach adopted by pathologists to
the assignment of the primary site during our trial led to
a proposal for unified criteria for tubo-ovarian site as-
signment [21] which has since been adopted in inter-
national pathology reporting [22] and clinical guidelines
[23].
The adjudication process used in the UKCTOCS trial
is not dissimilar to that used in the Prostate Lung Colo-
rectal and Ovarian Cancer screening trial [24]. In con-
trast to the cluster randomised trial of PSA testing for
prostate cancer [25] where data was abstracted into vi-
gnettes for expert review, we provided copies of original
clinical notes to the ORC members. To minimise ascer-
tainment bias, any reference to the trial/randomisation
arms was redacted in these documents. Review only
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occurred if the minimal required number of documents
was available. ORC members who were highly experi-
enced gynaecological oncology surgeons or pathologists
used an algorithm developed specifically during the trial
to assign a cancer site. To ensure accuracy and reprodu-
cibility over the years and across assessors, we audited
the reviews and introduced a classification algorithm
(Supplementary Figure 3, see Additional file 4). The re-
source implications of central adjudication can be sig-
nificant, as it requires many hours of highly trained
senior staff time. Often as in our trial, it is challenging
to estimate costs as reviewers usually volunteer their
time and work outside normal office hours. To save the
effort and cost of adjudication, we used individual as op-
posed to group adjudication, a work flow that involved
more than one assessment only when there was discrep-
ancy between the primary reviewer and registered ICD-
10 code, with group review limited to those where there
was discrepancy between two reviewers.
Adjudication also provides information on other key
variables such as staging and morphology which in the
past have been poorly documented by registries [26] but
now improving [27]. In our trial, we observed a stage
shift in the multimodal screening arm [6]. This would
not have been quantifiable using data from the registries
alone without the detailed review of all available clinical
documents as undertaken in UKCTOCS.
Kahan et al. [28] using a simulation model concluded
that outcome misclassification can lead to biased treat-
ment effect estimates and reduced power, potentially
resulting in an erroneous conclusion regarding efficacy.
The implementation of strategies to reduce misclassifica-
tion is therefore of critical importance in clinical trials. In
UKCTOCS, the main impact of adjudication was in im-
proving the accuracy of tubo-ovarian cancer. On death
outcomes, there was no significant difference on the mor-
tality impact of screening between the analyses which used
ORC-adjudicated disease-specific deaths and the sensitiv-
ity analysis limited to deaths with the disease-specific
ICD-10 codes (ICD-10 C56, C57 and C48) for tubo-
ovarian cancer [10].
Conclusion
Our data suggests that follow-up of trial participants for
tubo-ovarian cancer using national registry data will result
in incomplete ascertainment particularly of the site due in
part to the latency of registration. This can be reduced by
using hospital administrative data, which has shorter la-
tency. Central adjudication by experts though resource in-
tensive adds value by improving the accuracy of diagnoses.
Revised classification systems for ovarian cancer [8] will im-
prove accurate identification and aid reproducibility of site
assignment, but this will require pathologists and clinicians
to apply this new system uniformly across the globe.
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